We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Welcome to PracticeUpdate! We hope you are enjoying access to a selection of our top-read and most recent articles. Please register today for a free account and gain full access to all of our expert-selected content.
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
This meta-analysis of three placebo-controlled randomized controlled trials aimed to provide pooled effect estimates of the effect of tirzepatide therapy on blood pressure levels in individuals with overweight or obesity without type 2 diabetes. Participants treated with tirzepatide (all doses) had a significant reduction in both systolic and diastolic blood pressure in addition to significant weight loss and improvement in cardiometabolic risk factors.
Preliminary evidence suggests the role of tirzepatide in improving blood pressure in individuals with overweight or obesity without type 2 diabetes at baseline.
Tirzepatide is a novel dual gastric inhibitory polypeptide (GIP)/ glucagon-like peptide-1 (GLP-1) receptor co-agonist recently approved for the treatment of type 2 diabetes (T2D) and obesity. It represents an acylated peptide designed to activate the GIP and GLP-1 receptors, which are the key mediators of insulin secretion, but are also expressed in regions of the brain that regulate food intake. Tirzepatide reduces plasma glucose and body weight by enhancing β-cell function, delaying gastric emptying, downregulating insulin resistance, increasing satiation, and improving energy expenditure. The accumulating clinical evidence suggests that tirzepatide administration is associated with a significant reduction in body weight and meaningful improvements in various cardiometabolic risk markers, including blood pressure (BP), among overweight/obese individuals with and without T2D.